Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 249 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Parathyroid Hormone Clear all
Active, not recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
eneboparatide, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients

NCT01876732
View directory record Official record
Conditions
Vitamin B12 Deficiency
Interventions
Vitamin B12
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Effect of Teriparatide on Hip Fracture Healing

NCT01473589
View directory record Official record
Conditions
Femur Neck Fracture
Interventions
Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 29, 2026, 2:56 PM EDT
Terminated No phase listed Observational

Gene Expression in Hyperparathyroidism

NCT03044600
View directory record Official record
Conditions
Parathyroid Disease, Hyperparathyroidism
Interventions
Chart Review, HRPT2 Mutation Evaluation
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Second Study of the Effect of Teriparatide on Hip Fracture Healing

NCT01473602
View directory record Official record
Conditions
Femur Neck Fracture
Interventions
Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
19
States / cities
San Diego, California • Golden, Colorado • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 1 Interventional

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

NCT02274623
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia, Hyperparathyroidism, Secondary
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 29, 2026, 2:56 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D

NCT01329666
View directory record Official record
Conditions
Primary Hyperparathyroidism, Hypercalcemia, Vitamin D Deficiency, Osteoporosis, Osteopenia
Interventions
Placebo, Vitamin D3
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

NCT01796301
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romozosumab, Teriparatide
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Gainesville, Georgia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

NCT00343252
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture
Interventions
teriparatide, risedronate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

NCT00051558
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 29, 2026, 2:56 PM EDT
Not listed Phase 4 Interventional

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

NCT01173081
View directory record Official record
Conditions
Fractures
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
Ohio Orthopedic Center of Excellence
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Upper Arlington, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Vitamin D and Microbiota in Cystic Fibrosis

NCT02589444
View directory record Official record
Conditions
Vitamin D Deficiency, Cystic Fibrosis
Interventions
High-Dose Vitamin D3, Stool Sample, Sputum Sample, Sham Comparator, Blood draw
Dietary Supplement · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Use of NPSP558 in the Treatment of Hypoparathyroidism

NCT00732615
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Placebo, NPSP558
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Scottsdale, Arizona • Lakewood, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 29, 2026, 2:56 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Parathyroid Tumor Clonal Status

NCT05997810
View directory record Official record
Conditions
Parathyroid Tumor, Primary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT), Tertiary Hyperparathyroidism
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
839 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 29, 2026, 2:56 PM EDT
Completed No phase listed Observational

Coexisting Thyroid Disease and Hyperparathyroidism

NCT01306916
View directory record Official record
Conditions
Hyperthyroidism
Interventions
Not listed
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

NCT00743782
View directory record Official record
Conditions
Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Synthetic Human Parathyroid Hormone 1-34 pump
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
7 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 29, 2026, 2:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Vitamin D in Subjects With Alopecia Areata

NCT01328678
View directory record Official record
Conditions
Alopecia Areata
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2011 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

NCT01309399
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, placebo
Drug · Other
Lead sponsor
Health Research, Inc.
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

NCT00577863
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Huntsville, Alabama • Montgomery, Alabama • Peoria, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 29, 2026, 2:56 PM EDT
Completed No phase listed Observational

Quality of Life (QOL) Following Parathyroid Surgery

NCT00205452
View directory record Official record
Conditions
Parathyroidectomy
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 29, 2026, 2:56 PM EDT
Terminated Phase 4 Interventional

Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation

NCT06169735
View directory record Official record
Conditions
Parathyroid Dysfunction, Adenoma
Interventions
Indocyanine green, SPY Portable Handheld Imaging
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?

NCT01166958
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Raloxifene
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 89 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 29, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Vitamin D Supplementation on Muscle Mass and Function

NCT01199926
View directory record Official record
Conditions
Obesity, Insulin Resistance, Inflammation
Interventions
Vitamin D, Placebo
Dietary Supplement · Drug
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 35 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 29, 2026, 2:56 PM EDT
Recruiting No phase listed Observational

Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease

NCT03050762
View directory record Official record
Conditions
Endocrine Disease
Interventions
Data Collection, Follow Up
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 29, 2026, 2:56 PM EDT